Metamizol sodium + Triacetonamino-4-toluenesulfonate (Metamizolum natrium + Triacetonamino-4-toluensulfonas)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

NSAIDs - Pyrazolones

Included in the formulation
  • Tempalgin®
    pills inwards 
    Sopharma, AO     Bulgaria
  • Tempanginol®
    pills inwards 
    Balkanfarma - Dupnitsa AD     Bulgaria
    • АТХ:

    N.02.B.B.72   Metamizole sodium in combination with psycholeptics

    Pharmacodynamics:

    Combined drug.

    Metamizol sodium

    Non-selectively suppresses COX1 and COX2, regulating the synthesis of prostaglandins. It indiscriminately suppresses synthetases of prostaglandins. Suppresses the production of anti-inflammatory cytokines. Violates the synthesis of arachidonic acid. Has analgesic, antipyretic and anti-inflammatory effect. Inhibits the aggregation of platelets. With long-term use has a desensitizing effect.

    More analgesic effect, practically does not affect water-salt metabolism.

    Triacetonamino-4-toluenesulfonate

    Anxiolytic, blocks n-holinoretseptory, removes a state of fear and anxiety. Extends and enhances the action of metamizole sodium, eliminating emotional component of pain.

    Pharmacokinetics:

    Metamizol sodium

    After ingestion, up to 90% is absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is achieved in 1-2 hours. The connection with plasma proteins is 40%.

    The therapeutic effect develops 30 minutes after ingestion.

    Hydrolyses in the gastrointestinal tract to two active metabolites: 4-methylaminoantipyrine and 4-aminoantipyrine. Metabolism in the liver. Penetrates into breast milk.

    The half-life is 4 hours.

    Elimination by the kidneys.

    Triacetonamino-4-toluenesulfonate

    After oral administration, up to 80% is absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is reached after 30 minutes. The connection with plasma proteins is 60%.

    Metabolism in the liver.

    Half-life is 10 hours. Elimination by the kidneys, up to 75% unchanged.

    Indications:

    It is used for the treatment of headache and toothache, myalgia, arthralgia, neuralgia. Used for cholelithiasis, renal colic, dysmenorrhea, fever of unknown origin.

    ICD-10

    VI.G40-G47.G43   Migraine

    XI.K80-K87.K80.2   Stones of the gallbladder without cholecystitis

    XI.K80-K87.K80.5   Stones of the bile duct without cholangitis or cholecystitis

    XIII.M20-M25.M25.5   Pain in the joint

    XIII.M50-M54.M54.4   Lumbago with sciatica

    XIII.M70-M79.M79.1   Myalgia

    XIII.M70-M79.M79.2   Neuralgia and neuritis, unspecified

    XIV.N20-N23.N23   Renal colic, unspecified

    XIV.N80-N98.N94.6   Dysmenorrhea, unspecified

    XVIII.R10-R19.R10.4   Other and unspecified abdominal pain

    XVIII.R50-R69.R50   Fever of unknown origin

    XVIII.R50-R69.R51   Headache

    XXI.Z100.Z100 *   CLASS XXII Surgical Practice

    Contraindications:

    Hepatic and renal insufficiency, anemia in insufficiency of glucose-6-phosphate dehydrogenase, peptic ulcer and duodenal ulcer, oppression of hematopoiesis and respiration, hearing loss, arterial hypotension (below 100 mm Hg), age 15 years, pregnancy and lactation, individual intolerance.

    Carefully:

    Stomach ulcer and duodenal ulcer during remission, chronic heart failure, alcoholism, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Inside, after eating, 1 tablet 1-3 times a day.

    The highest daily dose: 1 tablet.

    The highest single dose: 4 tablets.

    Side effects:

    Central and peripheral nervous system: dizziness, headache.

    Respiratory system: shortness of breath, bronchospasm.

    Hemopoietic system: agranulocytosis, leukopenia, hemolytic anemia, aplastic anemia, thrombocytopenia.

    The cardiovascular system: tachycardia, arterial hypotension, cardiogenic shock.

    Digestive system: nausea, vomiting, decreased appetite, gastric bleeding, cholestasis, jaundice.

    Dermatological reactions: Lyell's syndrome (toxic epidermal necrolysis), Stevens-Johnson syndrome (erythema multiforme), urticaria.

    urinary system: proteinuria, polyuria, oligouria, interstitial nephritis.

    Allergic reactions.

    Overdose:

    Increased side effects.

    Treatment is symptomatic. With convulsive syndrome - intravenous diazepam and high-speed barbiturates.

    Interaction:

    Metamizole sodium enhances the effect of tricyclic antidepressants, allopurinol, analgesics, ethanol.

    Barbiturates and phenylbutazone reduce the effects of metamizole sodium.

    Metamizole sodium reduces the activity of coumarin anticoagulants and plasma levels of cyclosporine.

    With simultaneous application chloramphenicol with metamizole sodium increase the myelotoxic effects of metamizole sodium.

    With simultaneous application chlorpromazine with metamizole sodium increases the risk of hypothermia.

    Tratsetonamin-4-toluenesulfonate enhances the sedative effect of agents for general anesthesia,sleeping pills, narcotic and non-narcotic analgesics.

    Special instructions:

    Do not use the drug for more than 5 days.

    The drug can give a positive result in the conduct of doping control.

    During the treatment it is not recommended to drive vehicles and work with moving mechanisms.

    Instructions
    Up